TC Medical(SH:600763) Sou Hu Cai Jing·2025-08-23 03:22Financial Performance - For the first half of 2025, the company's operating revenue was 1.448 billion, an increase from 1.410 billion in the same period last year, reflecting a growth of approximately 2.7% [1] - The total profit for the same period was 419.921 million, compared to 406.937 million in the previous year, indicating a growth of about 3.1% [1] - The net profit attributable to shareholders was 321.157 million, up from 309.780 million year-on-year, representing an increase of approximately 3.5% [1] - The net cash flow from operating activities was 355.809 million, showing a year-on-year increase of 9.72% [29] Profitability Metrics - The weighted average return on equity for the first half of 2025 was 7.67%, a slight decrease of 0.14 percentage points compared to the previous year [27] - The return on invested capital for the same period was 6.79%, down by 0.08 percentage points year-on-year [27] Cash Flow Analysis - The net cash flow from financing activities was -306 million, a decrease of 155 million compared to the previous year [29] - The net cash flow from investment activities was -188 million, compared to -144 million in the same period last year [29] Asset and Liability Changes - As of the end of the first half of 2025, cash and cash equivalents decreased by 22.36% compared to the end of the previous year [40] - Long-term borrowings decreased by 100%, while non-current liabilities due within one year increased by 127.03% [43] Shareholder Structure - The largest shareholder, Hangzhou Baoqun Industrial Group Co., Ltd., held 33.89% of the total shares, with no change in its holding [54] - New shareholder, China Europe New Blue Chip Flexible Allocation Mixed Securities Investment Fund, replaced the previous quarter's shareholder [53] Valuation Ratios - As of August 22, 2025, the company's price-to-earnings ratio (TTM) was approximately 40.77, the price-to-book ratio (LF) was about 5.04, and the price-to-sales ratio (TTM) was around 7.18 [1]